Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
Growing
The company is in a growing phase, with the latest annual income totaling USD 62.90M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 62.90M.
Undervalued
The company’s latest PE is -12.71, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 228.36M shares, decreasing 12.58% quarter-over-quarter.
Held by Leon Cooperman
Star Investor Leon Cooperman holds 11.83M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.72.